High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer
DNA abnormalities are used in inclusion criteria of clinical trials for treatments with specific targeted molecules. MYC is one of the most powerful oncogenes and is known to be associated with triple-negative breast cancer (TNBC). Its DNA amplification is often part of the targeted DNA-sequencing p...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | 英語 |
| 出版事項: |
2019
|
| オンライン･アクセス: | https://doi.org/10.3390/ijms21010217 https://www.mdpi.com/1422-0067/21/1/217/pdf?version=1577502639 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|